{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:14:03Z","timestamp":1793121243223,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04561-z","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:05:37Z","timestamp":1765965937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinicopathological features of steroid-refractory immune-mediated hepatotoxicity induced by immune checkpoint inhibitors"],"prefix":"10.1186","volume":"26","author":[{"given":"Tomonobu","family":"Hioki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Goya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Kohjima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatake","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"373","key":"4561_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"02","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;02(373):23\u201334.","journal-title":"N Engl J Med"},{"issue":"387","key":"4561_CR2","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"30","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;30(387):1837\u201346.","journal-title":"Lancet"},{"key":"4561_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101184","volume":"8","author":"A Rousseau","year":"2023","unstructured":"Rousseau A, Parisi C, Barlesi F. Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open. 2023;8:101184.","journal-title":"ESMO Open"},{"issue":"11","key":"4561_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(11):158\u201368.","journal-title":"N Engl J Med"},{"key":"4561_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100170","volume":"2","author":"E De Martin","year":"2020","unstructured":"De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep. 2020;2:100170.","journal-title":"JHEP Rep"},{"key":"4561_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72:315\u201329.","journal-title":"Hepatology"},{"issue":"36","key":"4561_CR7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"10","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;10(36):1714\u201368.","journal-title":"J Clin Oncol"},{"key":"4561_CR8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s12072-021-10238-y","volume":"15","author":"T I Ito","year":"2021","unstructured":"I Ito T, Ishigami M, Yamamoto T, et al. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. Hepatol Int. 2021;15:1278\u201387.","journal-title":"Hepatol Int."},{"key":"4561_CR9","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119\u201342.","journal-title":"Ann Oncol."},{"issue":"5","key":"4561_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"21","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;21(5):95.","journal-title":"J Immunother Cancer"},{"key":"4561_CR11","first-page":"6129","volume":"28","author":"M S Dougan","year":"2020","unstructured":"S Dougan M, Blidner AG, Choi J, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer. 2020;28:6129\u201343.","journal-title":"Support Care Cancer."},{"key":"4561_CR12","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","volume":"160","author":"M Dougan","year":"2021","unstructured":"Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology. 2021;160:1384\u201393.","journal-title":"Gastroenterology"},{"key":"4561_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:387\u2013405.","journal-title":"J Natl Compr Canc Netw"},{"key":"4561_CR14","unstructured":"Japanese Society of Medical Oncology. Guidelines for Cancer Immunotherapy. 2nd ed. Tokyo: Kanehara & Co., Ltd.; 2019. (in Japanese)"},{"key":"4561_CR15","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u201315.","journal-title":"Clin Pharmacol Ther"},{"key":"4561_CR16","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"EASL Clinical Practice Guidelines","year":"2019","unstructured":"EASL Clinical Practice Guidelines. Drug-induced liver injury. J Hepatol. 2019;70:1222\u201361.","journal-title":"J Hepatol"},{"key":"4561_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005635","volume":"10","author":"A Coukos","year":"2022","unstructured":"Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S, et al. Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2022;10:e005635.","journal-title":"J Immunother Cancer"},{"issue":"372","key":"4561_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"22","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;22(372):320\u201330.","journal-title":"N Engl J Med"},{"issue":"378","key":"4561_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"05","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;05(378):1277\u201390.","journal-title":"N Engl J Med"},{"key":"4561_CR20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.gie.2019.09.009","volume":"90","author":"PT Kr\u00f6ner","year":"2019","unstructured":"Kr\u00f6ner PT, Mody K, Farraye FA. Immune checkpoint inhibitor-related luminal GI adverse events. Gastrointest Endosc. 2019;90:881\u201392.","journal-title":"Gastrointest Endosc"},{"key":"4561_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009431","volume":"96","author":"Z Wu","year":"2017","unstructured":"Wu Z, Lai L, Li M, Zhang L, Zhang W. Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: a case report. Medicine (Baltimore). 2017;96:e9431.","journal-title":"Medicine (Baltimore)"},{"key":"4561_CR22","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jhep.2018.06.012","volume":"69","author":"P Bhave","year":"2018","unstructured":"Bhave P, Buckle A, Sandhu S, Sood S. Mortality due to immunotherapy related hepatitis. J Hepatol. 2018;69:976\u20138.","journal-title":"J Hepatol"},{"key":"4561_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12328-023-01789-8","volume":"16","author":"A Nogami","year":"2023","unstructured":"Nogami A, Wada N, Muraoka E, et al. Mortality associated with the development of acute liver failure after a single dose of nivolumab. Clin J Gastroenterol. 2023;16:464\u20139.","journal-title":"Clin J Gastroenterol"},{"key":"4561_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/jhep.2002.30991","volume":"35","author":"MA Heneghan","year":"2002","unstructured":"Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology. 2002;35:7\u201313.","journal-title":"Hepatology"},{"key":"4561_CR25","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1007\/s10637-021-01136-z","volume":"39","author":"M Takinami","year":"2021","unstructured":"Takinami M, Ono A, Kawabata T, et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs. 2021;39:1716\u201323.","journal-title":"Invest New Drugs"},{"key":"4561_CR26","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","volume":"16","author":"J Luo","year":"2021","unstructured":"Luo J, Beattie JA, Fuentes P, et al. Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events. J Thorac Oncol. 2021;16:1759\u201364.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04561-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04561-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:36:27Z","timestamp":1768995387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04561-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4561"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04561-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"17 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Institutional Review Boards\/Ethics Committees of Kyushu University Hospital and Medical Institutions\u00a0(approval numbers: No. 23493) and was conducted in accordance with the principles of the Declaration of Helsinki. The requirement for written informed consent was waived because of the retrospective study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}